Long-term clinical remission in a patient with metastatic gastric cancer after palliative chemotherapy

被引：1

作者：

Teufel, A

Lehnert, T

Stremmel, W

Rudi, J

机构：

[1] Univ Heidelberg, Univ Klinikum, Med Klin 4, D-69115 Heidelberg, Germany

[2] Univ Heidelberg, Univ Klinikum, Chirurg Klin, D-69115 Heidelberg, Germany

来源：

ONKOLOGIE | 2000年 / 23卷 / 05期

关键词：

gastric cancer; R2; resection; palliative chemotherapy; long-term remission;

D O I：

10.1159/000027217

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: More than 50% of patients with gastric cancer initially present with locally advanced or metastatic disease. In general, gastric cancer in an advanced or metastatic stage is regarded as incurable. Despite treatment with palliative chemotherapy, the median survival time is stilt limited and does not exceed 12 months. Case Report:We report on a patient with advanced and metastatic gastric cancer who received palliative surgery and subsequent palliative chemotherapy. Results: Complete remission occurred after R2 resection and palliative chemotherapy. The patient is now disease-free for 10 years after the end of chemotherapy. Conclusions: Palliative chemotherapy for metastatic gastric cancer may seldom lead to long-term clinical remission.

引用

页码：464 / 466

页数：5

共 16 条

[1] GASTRIC-CANCER WITH BONE-MARROW INVASION AT PRESENTATION - CASE-REPORT AND REVIEW OF THE LITERATURE [J].

CRIVELLARI, D ;

CARBONE, A ;

SIGON, R ;

BUONADONNA, A ;

CANNIZZARO, R ;

SORIO, R ;

ROSSI, C ;

MONFARDINI, S .

TUMORI, 1995, 81 (01) :74-76

[2]

HAGIN GD, 1985, AM J GASTROENTEROL, V80, P835

[3] FAMTX VERSUS ETOPOSIDE, DOXORUBICIN, AND CISPLATIN - A RANDOM ASSIGNMENT TRIAL IN GASTRIC-CANCER [J].

KELSEN, D ;

ATIQ, OT ;

SALTZ, L ;

NIEDZWIECKI, D ;

GINN, D ;

CHAPMAN, D ;

HEELAN, R ;

LIGHTDALE, C ;

VINCIGUERRA, V ;

BRENNAN, M .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :541-548

[4] CHEMOTHERAPEUTIC PROTOCOL IN THE TREATMENT OF METASTASIZING GASTRIC-CARCINOMA - METHOTREXATE, ADRIAMYCIN AND 5-FLUOROURACIL [J].

KLEIN, HO ;

WICKRAMANAYAKE, PD ;

DIETERLE, F ;

MOHR, R ;

OERKERMANN, H ;

BROCK, J ;

BEYER, D ;

GROSS, R .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1982, 107 (45) :1708-1712

[5]

Neugut AI, 1996, SEMIN ONCOL, V23, P281

[6]

Petrasch S., 1998, Verdauungskrankheiten, V16, P167

[7] PHASE-II STUDY WITH THE COMBINATION ETOPOSIDE, DOXORUBICIN, AND CISPLATIN IN ADVANCED MEASURABLE GASTRIC-CANCER [J].

PREUSSER, P ;

WILKE, H ;

ACHTERRATH, W ;

FINK, U ;

LENAZ, L ;

HEINICKE, A ;

MEYER, J ;

MEYER, HJ ;

BUENTE, H .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1310-1317

[8]

Sobin LH, 1997, TNM CLASSIFICATION M

[9] Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial [J].

Waters, JS ;

Norman, A ;

Cunningham, D ;

Scarffe, JH ;

Webb, A ;

Harper, P ;

Joffe, JK ;

Mackean, M ;

Mansi, J ;

Leahy, M ;

Hill, A ;

Oates, J ;

Rao, S ;

Nicolson, M ;

Hickish, T .

BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) :269-272

[10]

WILKE H, 1990, INVEST NEW DRUG, V8, P65

← 1 2 →